Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis (Q33747440)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

colorectal cancer

1 reference

based on heuristic

inferred from title

pharmacogenomics

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

Mariano Ponz-Sarvise

object named as

M Ponz-Sarvise

5

0 references

object named as

A Chopitea

9

0 references

author name string

R Zarate

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

J Rodríguez

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

E Bandres

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

A Patiño-Garcia

4

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

A Viudez

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

N Ramirez

7

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

N Bitarte

8

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

J Gacía-Foncillas

10

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

language of work or name

0 references

publication date

9 March 2010

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

102

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

987-994

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844042

21 June 2018

Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844042

21 June 2018

GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844042

21 June 2018

UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844042

21 June 2018

OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844042

21 June 2018

Systemic therapy for metastatic colorectal cancer: current options, current evidence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844042

21 June 2018

Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844042

21 June 2018

A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844042

21 June 2018

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844042

21 June 2018

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844042

21 June 2018

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844042

21 June 2018

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844042

21 June 2018

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844042

21 June 2018

The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844042

21 June 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844042

21 June 2018

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844042

21 June 2018

Importance of glutathione and associated enzymes in drug response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844042

21 June 2018

Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844042

21 June 2018

Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605595

21 January 2018

Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605595

21 January 2018

Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605595

21 January 2018

Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605595

21 January 2018

Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605595

21 January 2018

Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605595

21 January 2018

Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605595

21 January 2018

Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605595

21 January 2018

Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605595

21 January 2018

Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605595

21 January 2018

Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605595

21 January 2018

Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605595

21 January 2018

First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605595

21 January 2018

Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605595

21 January 2018

Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605595

21 January 2018

Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605595

21 January 2018

8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605595

21 January 2018

Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844042

30 October 2018

Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844042

30 October 2018

Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20216541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estimates of cancer incidence and mortality in Europe in 1995

1 reference

https://pubmed.ncbi.nlm.nih.gov/20216541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/20216541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20216541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of a novel single nucleotide polymorphism in the first tandem repeat sequence of the thymidylate synthase 2R allele

1 reference

https://pubmed.ncbi.nlm.nih.gov/20216541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20216541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

GSTP1 and MTHFR polymorphisms are related with toxicity in breast cancer adjuvant anthracycline-based treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/20216541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20216541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined analysis of germline polymorphisms of p53, GSTM1, GSTT1, CYP1A1, and CYP2E1: relation to the incidence rate of cervical carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20216541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6605595

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Dimensions Publication ID

0 references

release_3jvkfy5gffakznmonwudmkisqe

1 reference

https://api.fatcat.wiki/v0/release/3jvkfy5gffakznmonwudmkisqe

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33747440&oldid=2195729415"